C.R. Bard downgraded to Sell from Underperform at CLSA CLSA downgraded CR Bard based on concerns its risk profile has increased with its new multi-year-plan following disappointing guidance. Price target lowered to $96 from $98.
News For BCR From The Last 14 Days
Check below for free stories on BCR the last two weeks.
Medtronic data positive for C.R. Bard, says Barclays Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.